IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
CZ
Overseen byCaicun Zhou
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 1 & 2
Recruiting
Sponsor: InxMed (Shanghai) Co., Ltd.
No Placebo Group
Trial Summary
What is the purpose of this trial?
This is a multicenter, open-label, phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and antitumor efficacy of IN10018 in combination with third-generation EGFR-TKI (Furmonertinib is the proposed) in previously-treated or naïve advanced EGFR-mutation positive NSCLC.
Research Team
CZ
Caicun Zhou
Principal Investigator
Shanghai Pulmonary Hospital, Shanghai, China
Eligibility Criteria
Inclusion Criteria
You must comprehend and consent to the terms of this agreement.
You can expect to live for at least three months.
You are a male or female adult of 18 years or older, and you have provided consent to participate.
See 7 more
Treatment Details
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Experimental Group in cohort 1, cohort 2, and cohort 3Experimental Treatment2 Interventions
IN10018+Furmonertinib
Group II: Control Group in cohort 3Active Control1 Intervention
Furmonertinib
Find a Clinic Near You
Who Is Running the Clinical Trial?
InxMed (Shanghai) Co., Ltd.
Lead Sponsor
Trials
11
Recruited
1,300+